| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we analyzed the anti-tumor effect of the recombinant bifidobacteria secreting the immunotoxin, anti-EGFR antibody / Pseudomonas Exotoxin A fusion protein, in animal models of human cancer. As the result, the bacteria exhibits significant anti-tumor activity on human cancer cells expressing EGFR. In addtion, we demonstrated that this immunotoxin specifically inhibited the proliferation of target cancer cells both in molecular and cellular level. Taken together, we consider that this bifidobacteria can be actually utilized for the novel therapy for cancers.
|
